Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Pneumologie ; 77(9): 639-644, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38452864

RESUMEN

We report a patient with severe cavitary pulmonary tuberculosis and Aspergillus niger superinfection, whose only comorbidity was untreated diabetes mellitus. A. niger pneumonia was proven by PCR, sequencing and culture of pleural and respiratory secretions. The patient was successfully treated with a four-drug antituberculous regimen, liposomal amphotericin B (up to 5 mg/kg/d) and pleuro-pneumonectomy. Histology of the resected lung revealed destroyed lung tissue with inflammatory cells and fungal conidia. There were large deposits of polarising material, which was found to be calcium oxalate. There was also nodular caseating necrosis bordered by epitheloid cells and connective tissue. Thus, all diagnostic criteria for invasive A. niger infection were met. Several local risk factors, such as extensive lung damage and tissue acidification, may have favoured superinfection by A. niger. This case highlights the diagnostic value of calcium oxalate crystals in lung tissue and the need for combined antimicrobial and surgical treatment in extensive invasive aspergillosis caused by A. niger.


Asunto(s)
Aspergilosis , Aspergillus , Enfermedades Pulmonares Fúngicas , Neumonía , Sobreinfección , Tuberculosis Pulmonar , Humanos , Aspergillus niger , Oxalato de Calcio/análisis , Sobreinfección/diagnóstico , Sobreinfección/complicaciones , Enfermedades Pulmonares Fúngicas/complicaciones , Enfermedades Pulmonares Fúngicas/diagnóstico , Enfermedades Pulmonares Fúngicas/microbiología , Aspergilosis/diagnóstico , Aspergilosis/microbiología , Aspergilosis/patología , Neumonía/complicaciones , Tuberculosis Pulmonar/complicaciones , Tuberculosis Pulmonar/diagnóstico , Tuberculosis Pulmonar/tratamiento farmacológico
2.
Infection ; 47(3): 425-433, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-30649684

RESUMEN

PURPOSE: We studied the incidence, morbidity and mortality of all patients presenting in our teaching hospital with proven influenza virus and/or respiratory syncytial virus (RSV) infection during the influenza epidemic season 2018 which was characterized by a predominant incidence of influenza virus B type B of the Yamagata line. METHODS: In the fall of 2017, specific precaution measures in addition to standard measures were implemented, including standardized testing for influenza virus A,B and RSV by multiplex PCR of pharyngeal swabsData from all consecutive patients were analyzed retrospectively. RESULTS: Overall 651 patients were examined for the presence of influenza virus and RSV; 214 patients had influenza virus A (n = 36), B (n = 152), and/or RSV (n = 30), including four patients with dual infection. 86% of cases had influenza virus (80% B), and 14% RSV infection. N = 23 cases were treated as outpatients. The rate of acute viral respiratory infections (influenza virus and RSV) was 191 of 2776 (6.9%) admissions to medical wards. Of n = 191 hospitalized cases, n = 44 cases (20.6%) had nosocomial infection. Viral infections were associated with a high morbidity (pneumonia 28.5%, mortality 4.7%). Independent predictors of prolonged hospitalization were the presence of pneumonia, NIV and renal complications, and independent predictors of pneumonia were age ≥ 65 years, bedridden status and CRP ≥ 2.9 mg/dL. CONCLUSIONS: The rate of nosocomial cases was high despite established precaution measures. RSV was associated with morbidity and mortality comparable to influenza. Pneumonia remains the main complication of acute viral respiratory infections, and antimicrobial treatment should include both antiviral as well as antibacterial agents.


Asunto(s)
Coinfección/epidemiología , Epidemias , Gripe Humana/epidemiología , Infecciones por Virus Sincitial Respiratorio/epidemiología , Enfermedad Aguda/epidemiología , Enfermedad Aguda/mortalidad , Adulto , Anciano , Coinfección/mortalidad , Coinfección/virología , Infección Hospitalaria/epidemiología , Infección Hospitalaria/mortalidad , Infección Hospitalaria/virología , Femenino , Alemania/epidemiología , Hospitalización/estadística & datos numéricos , Humanos , Virus de la Influenza A/fisiología , Virus de la Influenza B/fisiología , Gripe Humana/mortalidad , Gripe Humana/virología , Masculino , Persona de Mediana Edad , Morbilidad , Infecciones por Virus Sincitial Respiratorio/mortalidad , Infecciones por Virus Sincitial Respiratorio/virología , Virus Sincitiales Respiratorios/fisiología , Estudios Retrospectivos , Adulto Joven
3.
Dtsch Med Wochenschr ; 142(16): 1211-1216, 2017 Aug.
Artículo en Alemán | MEDLINE | ID: mdl-28810278

RESUMEN

In patients with home ventilation, there is a markedly higher probability for lower respiratory infections or pneumonia and severe courses due to comorbidity. Tracheobronchitis and pneumonia are often difficult to distinguish. Tracheobronchitis with pronounced secretion which can't be controlled otherwise can be an indication for antimicrobial therapy.There are no data available in order to establish a recommendation for the initial empiric calculated antimicrobial therapy in patients with home ventilation. However, risk factors for multi drug resistance (MDR) are mostly present and should be considered in the selection of antimicrobial therapy.The principles of antimicrobial therapy are also essential for infections in home ventilation: judicious indication, dosage, microbiological investigation, de-escalation and duration of therapy. In individual cases, inhaled antimicrobials are an option.In order to avoid lower airway infections, adherence to hygienic standards is essential. In addition, invasive ventilation should be avoided wherever possible. If possible, weaning attempts are to be repeated given that invasive ventilation is a risk factor for pneumonia caused by aspiration.


Asunto(s)
Neumonía Bacteriana , Neumonía Asociada al Ventilador , Respiración Artificial/efectos adversos , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Bacterias/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple , Humanos , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/epidemiología , Neumonía Bacteriana/microbiología , Neumonía Asociada al Ventilador/tratamiento farmacológico , Neumonía Asociada al Ventilador/epidemiología , Neumonía Asociada al Ventilador/microbiología , Factores de Riesgo
5.
Lung ; 194(2): 185-91, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26748496

RESUMEN

BACKGROUND: The evaluation of the role of novel biomarkers in the management of cardiac and pulmonary conditions has received particular attention in recent years. A further particular perspective is the use of biomarker panels in the evaluation of patients presenting with acute dyspnea. METHODS: We prospectively evaluated three biomarkers (MR-proANP, PCT, and MR-proADM) in consecutive patients presenting with acute dyspnea in a medical emergency unit during a 4-week period. Patients received a final diagnosis. Biomarkers were tested for their potential to predict diagnoses and survival. No intervention was done. RESULTS: Overall, n = 172 patients were included. Of these, 32.6 % had acute heart failure, 16.9 % pneumonia, and 5.8 % died. MR-proANP was the highest in patients with acute heart failure and lung embolism. Dyspnea scores and levels of MR-pro-ANP correlated positively. MR-proANP achieved an AUC of 0.83 for the diagnosis of acute heart failure. Using a cut-off of 120 pmol/l, sensitivity was 91.1 % and specificity 50 %. PPV was 46.8 % and NPV 92.1 %. In patients with MR-proANP >300 pmol/l, PPV raised to 67.3 %. MR-proADM had an AUC of 0.84 for the prediction of death. PPV was 16 % and NPV 98.4 %. The AUC of PCT was 0.74 for the diagnosis of pneumonia. Using a cut-off of 0.25 ng/ml, PCT had a sensitivity of 44.8 % and a specificity of 85.3 %. PPV was 38.2 and NPV 88.4 %. Using a lower cut-off of <0.1 ng/ml, NPV reached 92.9 %. CONCLUSIONS: A panel of three biomarkers (MR-proANP, PCT, and MR-proADM) in patients presenting to the emergency unit with acute dyspnea provides information about the probability of acute heart failure, nonsurvival, and pneumonia. These biomarkers achieve low to moderate positive predictive values (PPV) and high negative predictive values (NPV).


Asunto(s)
Adrenomedulina/sangre , Factor Natriurético Atrial/sangre , Calcitonina/sangre , Disnea/sangre , Servicio de Urgencia en Hospital , Insuficiencia Cardíaca/sangre , Neumonía/sangre , Precursores de Proteínas/sangre , Enfermedad Aguda , Anciano , Anciano de 80 o más Años , Área Bajo la Curva , Biomarcadores/sangre , Disnea/diagnóstico , Disnea/etiología , Disnea/mortalidad , Femenino , Insuficiencia Cardíaca/complicaciones , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Neumonía/complicaciones , Neumonía/diagnóstico , Neumonía/mortalidad , Valor Predictivo de las Pruebas , Pronóstico , Estudios Prospectivos , Curva ROC , Reproducibilidad de los Resultados , Factores de Riesgo , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA